# NutriBand Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/NutriBand Inc.). ## Overview Nutriband Inc. is a U.S.-based pharmaceutical development and services company focused on transdermal drug-delivery products and abuse-deterrent patch technology. Through its subsidiaries, it also provides contract manufacturing and contract research and development services for health, wellness, pharmaceutical, and medical device customers. ## Products & services • AVERSA™ abuse-deterrent transdermal technology • Transdermal pharmaceutical product development • Contract manufacturing for topical and transdermal products • Contract research and development services • Consumer health, OTC, and tape product services - **AVERSA transdermal products** (10%) — Development of abuse-deterrent patch-based drug delivery products using AVERSA technology. - **Contract manufacturing** (70%) — Manufacturing services for health, wellness, OTC, topical, and transdermal products. - **Contract R&D services** (20%) — Research and development services for pharmaceutical and medical device customers. - AVERSA™ abuse-deterrent transdermal technology - Transdermal pharmaceutical product development - Contract manufacturing for topical and transdermal products - Contract research and development services - Consumer health, OTC, and tape product services ## Customers Nutriband sells services to health and wellness, over-the-counter, pharmaceutical, and medical device customers, while its product-development work is aimed at drug companies that use transdermal delivery. Its AVERSA platform is relevant to customers seeking to reduce abuse, diversion, misuse, and accidental exposure in opioid and stimulant patches. - **Health and wellness / OTC customers** (primary) — Buy contract manufacturing for transdermal, topical, and tape products. - **Pharmaceutical customers** (primary) — Use contract manufacturing and AVERSA-related development for drug patches. - **Medical device customers** (secondary) — Buy contract R&D services related to product development and testing. - **Drug-delivery partners** (primary) — Collaborate on AVERSA-based transdermal products and clinical supply work. - Health and wellness brands needing transdermal manufacturing - OTC pharmaceutical customers outsourcing patch production - Pharmaceutical companies seeking abuse-deterrent patch IP - Medical device customers buying R&D support - Drug developers focused on opioid and stimulant delivery ## Geography Nutriband is headquartered in Orlando, Florida, and its manufacturing operations are centered in Cherryville, North Carolina. The company states that it primarily operates and derives most of its revenues in the United States, while some financing activity has involved investors outside the U.S. - **United States** (90%) — Company states it primarily operates and derives most revenues in the U.S. - **International** (10%) — Includes non-U.S. financing and potential future collaboration exposure. - Headquartered in Orlando, Florida - Manufacturing facility in Cherryville, North Carolina - Most revenue is generated in the United States - European investors participated in a private financing - U.S. regulatory exposure is central to product development ## Strategy Nutriband's strategy centers on advancing AVERSA-based transdermal products through development and regulatory pathways, while using contract manufacturing and R&D services to support current operations. The company also relies on partnerships, including with Kindeva Drug Delivery, to share development costs and move lead programs forward. - **Advance AVERSA lead product development** (medium-term) — The platform is the core proprietary asset and the main long-term value driver. - **Expand contract manufacturing utilization** (short-term) — Manufacturing services provide operating revenue and support facility economics. - **Maintain external development partnerships** (medium-term) — Shared-cost collaborations reduce funding burden and add technical capability. - Advance AVERSA abuse-deterrent patch technology - Use partnerships to share development and clinical supply costs - Support operations through contract manufacturing revenue - Maintain contract R&D capabilities for life sciences customers - Pursue FDA-regulated transdermal product development ## Risks Nutriband faces development, regulatory, and funding risk because its lead products depend on FDA approval and successful clinical and manufacturing execution. The company also has concentration risk in a small number of service relationships and product-development programs, making revenue and progress uneven. - **FDA and regulatory approval risk** [high] — Transdermal drug products must clear lengthy regulatory review before commercialization. - **Product safety and liability risk** [high] — Unexpected adverse events or misuse concerns could trigger recalls or enforcement. - **Customer concentration and program dependence** [medium] — Contract manufacturing and R&D revenue can be tied to a limited set of customers. - **Financing and liquidity risk** [high] — Development-stage companies often need external capital to fund R&D and operations. - FDA approval timing can delay product commercialization - Abuse-deterrent claims may be difficult to prove and maintain - Revenue depends on a small number of service and development programs - Product safety or recall issues could damage reputation and sales - Capital needs may require additional financing ## Accounting Revenue recognition depends on whether Nutriband is shipping products or performing services, with product revenue recognized on shipment and service revenue recognized over time as work is completed. Investors should also watch deferred revenue, going-concern judgments, and estimates around receivables, leases, and R&D spending because these can materially affect reported results and liquidity presentation. - **Revenue recognition under contracts with customers** — Product sales are point-in-time; R&D services are recognized over time. - **Deferred revenue** — Can shift revenue between periods. - **Going concern and liquidity estimates** — Affects disclosure, investor perception, and capital structure analysis. - **Lease accounting** — Impacts leverage and fixed-obligation analysis. - **R&D expense recognition** — Suppresses near-term earnings while supporting pipeline investment. - Product revenue recognized when goods ship to customers - Service revenue recognized over time as work is performed - Deferred revenue arises when cash is received before performance - Going-concern assessment depends on cash, borrowings, and forecasts - Lease liabilities affect balance sheet leverage and fixed costs --- *Last updated: 2026-04-29T04:42:11.227593+00:00*